A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday.
The U.S. Food and Drug Administration approved Eli Lilly’s drug, named Zepbound. The drug, also known as tirzepatide, helped dieters lose as much as 40 to 60 pounds in testing.
The results are that they were only tested on perfectly healthy people which is not indicative of their success in the general population, and the results were also that most people gained the weight back immediately upon stopping the drug.
The side effects were not too bad for people getting the drug for free, but at 1k a month, those side effects cause much higher drop out rates as well.
Still way more promising than anything else available, but not that promising overall.